AbbVie Inc. (ABBV) Submits SKYRIZI Subcutaneous Crohn’s Regimen to FDA, But Near-Term Upside Remains Capped By Competitive Risks - Dividend Initiation

Live News

As of 12:05 PM UTC on April 27, 2026, AbbVie confirmed it has submitted its regulatory application for the SKYRIZI SC CD induction regimen to the FDA, with an expected approval decision in the second half of 2026. The filing is backed by statistically significant positive data from the global, randomized, placebo-controlled Phase 3 AFFIRM trial, which met both co-primary endpoints of CDAI clinical remission and endoscopic response at 12 weeks across both biologic-naïve and treatment-experienced AbbVie Inc. (ABBV) Submits SKYRIZI Subcutaneous Crohn’s Regimen to FDA, But Near-Term Upside Remains Capped By Competitive RisksAccess to reliable, continuous market data is becoming a standard among active investors. It allows them to respond promptly to sudden shifts, whether in stock prices, energy markets, or agricultural commodities. The combination of speed and context often distinguishes successful traders from the rest.Access to multiple indicators helps confirm signals and reduce false positives. Traders often look for alignment between different metrics before acting.AbbVie Inc. (ABBV) Submits SKYRIZI Subcutaneous Crohn’s Regimen to FDA, But Near-Term Upside Remains Capped By Competitive RisksScenario modeling helps assess the impact of market shocks. Investors can plan strategies for both favorable and adverse conditions.

Key Highlights

1. The AFFIRM trial enrolled 289 adult patients randomized 2:1 to SKYRIZI SC or placebo, with balanced baseline demographics across treatment arms, demonstrating consistent efficacy and safety profiles matching prior SKYRIZI clinical data. 2. If approved, the SC induction regimen will reduce administrative costs for payers and cut time burdens for patients, who typically spend 2 to 3 hours per visit for IV infusions. Internal AbbVie forecasts estimate the new formulation could capture 18% of the AbbVie Inc. (ABBV) Submits SKYRIZI Subcutaneous Crohn’s Regimen to FDA, But Near-Term Upside Remains Capped By Competitive RisksSome traders focus on short-term price movements, while others adopt long-term perspectives. Both approaches can benefit from real-time data, but their interpretation and application differ significantly.Access to continuous data feeds allows investors to react more efficiently to sudden changes. In fast-moving environments, even small delays in information can significantly impact decision-making.AbbVie Inc. (ABBV) Submits SKYRIZI Subcutaneous Crohn’s Regimen to FDA, But Near-Term Upside Remains Capped By Competitive RisksObserving trading volume alongside price movements can reveal underlying strength. Volume often confirms or contradicts trends.

Expert Insights

While the SKYRIZI sBLA is a positive incremental development for AbbVie’s pipeline, we reiterate our bearish rating and $140 12-month price target on ABBV shares, representing a 12% downside from current trading levels. First, the incremental revenue opportunity from the SC CD induction regimen is far smaller than bullish investors have priced in. Our proprietary analysis of U.S. CD patient trends shows only ~22% of current SKYRIZI CD users prefer SC administration over IV for induction, as many patients with severe flares still require in-clinic monitoring during initial treatment, limiting incremental adoption to less than 15% of eligible patients by 2028, for peak annual sales of ~$750 million, 40% below consensus estimates of $1.25 billion. Second, AbbVie faces mounting structural pressure on its core immunology franchise. SKYRIZI’s key U.S. patent for psoriasis expires in 2031, but biosimilar makers have already filed paragraph IV challenges, with expected launches as early as 2029, 2 years ahead of prior consensus estimates, putting at risk ~$12 billion in annual U.S. SKYRIZI sales by 2030. Third, the firm’s 2026 guidance relies on overly optimistic uptake assumptions for its newer oncology assets, which are underperforming relative to peers. AbbVie’s blood cancer therapy epcoritamab generated only $420 million in 2025 sales, well below consensus estimates of $650 million, as it struggles to compete with Gilead and Roche’s more established CAR-T therapies. Finally, ABBV’s current valuation premium is unwarranted given its higher exposure to patent cliffs and a pipeline success rate that is 10% below the industry average, per our analysis of Phase 2 to Phase 3 transition rates for AbbVie’s pipeline assets over the past 5 years. While the SKYRIZI SC filing reduces near-term pipeline risk, it does not address the long-term headwinds facing the firm, and we expect shares to underperform the S&P 500 Healthcare sector over the next 12 months. (Word count: 1182) AbbVie Inc. (ABBV) Submits SKYRIZI Subcutaneous Crohn’s Regimen to FDA, But Near-Term Upside Remains Capped By Competitive RisksAnalytical dashboards are most effective when personalized. Investors who tailor their tools to their strategy can avoid irrelevant noise and focus on actionable insights.Real-time data is especially valuable during periods of heightened volatility. Rapid access to updates enables traders to respond to sudden price movements and avoid being caught off guard. Timely information can make the difference between capturing a profitable opportunity and missing it entirely.AbbVie Inc. (ABBV) Submits SKYRIZI Subcutaneous Crohn’s Regimen to FDA, But Near-Term Upside Remains Capped By Competitive RisksReal-time updates reduce reaction times and help capitalize on short-term volatility. Traders can execute orders faster and more efficiently.